Economic Observation Network The core product of Xinqiao Biotechnology, Givasomig, will present updated research data at the annual meeting of the European Society of Oncology on October 25, 2026. The performance of efficacy data will affect the subsequent registration process.

Product development progress:
The toughest moment will be on October 25, 2026, when Givasomig will present the updated data of the Ib phase combined dose extension study in the form of a poster at the annual meeting of the European Society of Oncology (ESMO) The ORR of the 8mg/kg dose group previously announced in January was 77%, and the mPFS was 16.9 months. If this updated data can maintain or even improve this number in a larger sample, it will be a strong validation on the registration path; On the contrary, any safety signals or efficacy attenuation will be amplified and interpreted.

The above content is based on publicly available information and does not constitute investment advice.